Research and Clinical Trials

A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson’s Disease
Brief Description  
  1. To assess the efficacy of rasagiline 1 mg as add on treatment to dopamine agonist therapy in early PD patients not optimally controlled on dopamine agonists.
  2. To investigate whether rasagiline affects the adverse event profile of the dopamine agonists.
  3. To characterize the efficacy of rasagiline on reducing disability, including non-motor symptoms.
Who may be Eligible  
  • Patients receiving a stable dose of oral ropinirole or pramipexole whose symptoms are not optimally controlled or whose oral dopamine agonist titration regimen was changed due to intolerability
  • Males and females.
  • Age = 30 years
  • Parkinson’s disease with presence of at least two of the cardinal signs (resting tremor, bradykinesia, rigidity), without other known or suspected cause of Parkinsonism
PD - Parkinson Disease
IRB Number  
Principal Investigator  
Iyer, Sanjay

For More Information, Contact  Jacqueline  , Foster
Phone:  (704) 446-1909  Fax:  (704) 446-1915  
Address:1010 Edgehill Road North Charlotte, NC 28207